Is sorafenib effective against hepatocellular carcinoma?

Results from the multinational, randomized, placebo-controlled, three-phase sorafenibHCC Evaluation of Randomized Protocol(SHARP) trial show significant improvement with sorafenib The overall survival rate(OS) and drug-related adverse reactions of patients with advanced HCC with good liver function were measured. Sorafenib is more optimistic about hepatocellular carcinoma. Sorafenib targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are involved in tumor cell proliferation and tumor angiogenesis. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.